Clinical Trials · NCT06804603
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Vanda Pharmaceuticals
- Enrollment
- 124
- Start date
- Feb 2025
- Locations
- 3 sites, United States
- Primary endpoint
- Proportion of participants with at least 1 vomiting episode per week in the tradipitant group compared to the placebo group as measured by a daily symptom diary.